BioNTech
- Country
- π©πͺGermany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in M...
Safety, Effectiveness, and Pharmacokinetics (the Movement of Drug Into, Through and Out of the Body) of BNT327 (an Investigational Therapy) in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 982
- Registration Number
- NCT06712316
Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 439
- Registration Number
- NCT06712355
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 1350
- Registration Number
- NCT06683352
- Locations
- πΊπΈ
Artemis Institute for Clinical Research, San Diego, California, United States
πΊπΈClinical Research Consulting, Milford, Connecticut, United States
πΊπΈMiami Dade Medical Research Institute, LLC, Miami, Florida, United States
A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 96
- Registration Number
- NCT06469164
- Locations
- πΊπΈ
UAB Sexual Health Research Clinic, Birmingham, Alabama, United States
πΊπΈChattanooga Medical Research, LLC (for Part B only), Chattanooga, Tennessee, United States
πΊπΈPraetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 110
- Registration Number
- NCT06449209
- Locations
- πΊπΈ
Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
πΊπΈTallahassee Memorial Physician Partners - Cancer & Hematology Specialists, Tallahassee, Florida, United States
πΊπΈCarle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 70
- Registration Number
- NCT06449222
- Locations
- πΊπΈ
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
πΊπΈCarle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
πΊπΈBozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana, United States
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 468
- Registration Number
- NCT06340568
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 8798
- Registration Number
- NCT06178991
- Locations
- πΊπΈ
Velocity Clinical Research, Cincinnati, Mt. Auburn, Cincinnati, Ohio, United States
πΊπΈNorth Alabama Research Center, Athens, Alabama, United States
πΊπΈAccel Research Sites - Birmingham Clinical Research Unit, Birmingham, Alabama, United States
Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 360
- Registration Number
- NCT06150183
- Locations
- πΊπΈ
Cleveland Clinic, Cleveland, Ohio, United States
π§πͺGZA Ziekenhuizen, Antwerpen, Belgium
π§πͺCHU de LiΓ¨ge, Liege, Belgium
Safety, Tolerability, and Efficacy of mFOLFIRINOX Β± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 320
- Registration Number
- NCT06069778
- Locations
- πΊπΈ
Clinical Research Alliance, Westbury, New York, United States
πΊπΈValkyrie Clinical Trials, Los Angeles, California, United States
πΊπΈPrisma Health Cancer Institute, Greenville, South Carolina, United States